Quidel Ortho Reagents, Consumables and Maintenance

SOL #: HT9408-26-REAGENTSources Sought

Overview

Buyer

DEPT OF DEFENSE
Defense Health Agency (Dha)
DEFENSE HEALTH AGENCY
SAN ANTONIO, TX, 78230, United States

Place of Performance

GOULDS, FL

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

In Vitro Diagnostic Substances, Reagents, Test Kits And Sets (6550)

Set Aside

No set aside specified

Timeline

1
Posted
Mar 27, 2026
2
Response Deadline
Apr 6, 2026, 5:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – South (HCD-S) is conducting market research through a Sources Sought notice to identify capable sources for providing Quidel Ortho Reagents, Consumables, and Maintenance. This requirement supports two Government-owned Quidel Ortho, Vision Swift Analyzers at the 96th Medical Group Elgin AFB, FL. Responses are due by April 6, 2026, at 12:00 P.M. CT.

Scope of Work

The Government requires the provision and delivery of specific reagents and consumables, all of which must be FDA approved and compatible with the Quidel Ortho, Vision Swift Analyzers. A detailed list of required items, including MTS A/B/D Group, MTS Anti-IgG cards, RESOLVE panels, and various diluents and trays, is provided. Additionally, the requirement includes technical support and maintenance, encompassing routine software upgrades and readily available field service engineers (FSEs) for on-site repairs.

Contract & Timeline

  • Type: Sources Sought / Request for Information (RFI)
  • NAICS: 325413, In-Vitro Diagnostic Substance Manufacturing (firms may recommend alternatives with rationale)
  • Set-Aside: May be set aside for Small Business or procured through Full and Open competition, based on RFI responses.
  • Response Due: April 6, 2026, 12:00 P.M. CT
  • Published: March 27, 2026

Evaluation

This RFI is for informational and planning purposes only. Responses will be used by DHACA HCD-S for market research to identify potential interested, capable, responsible, and qualified commercial offerors. The information will help determine the appropriate acquisition strategy, including potential small business set-asides.

Submission Requirements

Interested parties, especially small businesses, are encouraged to submit responses to the market survey questions. Submissions must include:

  • Entity Name, Point of Contact, Phone, Email, CAGE Code, UEI
  • A one-page capability statement demonstrating ability to meet the requirement
  • SAMS registration status (Yes/No)
  • Small business status (Yes/No) and specific certifications (8(a), HUBZone, SDVOSB, SDB, EDWOSB, WOSB, VOSB) under NAICS 325413.

Contact Information

All correspondence regarding this RFI should be sent to:

People

Points of Contact

Robby BrinkmannPRIMARY
Marcus MattinglySECONDARY

Files

Files

No files attached to this opportunity

Versions

Version 1Viewing
Sources Sought
Posted: Mar 27, 2026
Quidel Ortho Reagents, Consumables and Maintenance | GovScope